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No neurocognitive advantage for immediate
antiretroviral treatment in adults with greater
than 500 CD4R T-cell counts
Edwina J. Wrighta, Birgit Grundb, Kevin R. Robertsonc,
Lucette Cysiqued, Bruce J. Brewe, Gary L. Collinsf,
Mollie Poehlman-Roedigerf, Michael J. Vjechag,
Augusto Cesar Penalva de Oliveirah, Barbara Standridgei, Cate Careyj,
Anchalee Avihingsanonk, Eric Florencel, Jens D. Lundgrenm,
Alejandro Arenas-Pinton, Nicolas J. Muellero, Alan Winstonp,
Moses S. Nsubugaq, Luxshimi Lalr, Richard W. Prices, for the
INSIGHT START Neurology Substudy Group
Objective: To compare the effect of immediate versus deferred antiretroviral treatment
(ART) on neuropsychological test performance in treatment-naive HIV-positive adults
with more than 500 CD4þ cells/ml.
Design: Randomized trial.
Methods: The START parent study randomized participants to commence immediate
versus deferred ART until CD4þ less than 350 cells/ml. The START Neurology substudy
used eight neuropsychological tests, at baseline, months 4, 8, 12 and annually, to
compare groups for changes in test performance. Test results were internally standard-
ized to z-scores. The primary outcomewas the average of the eight test z-scores (QNPZ-
8). Mean changes in QNPZ-8 from baseline were compared by intent-to-treat using
longitudinal mixed models. Changes from baseline to specific time points were
compared using ANCOVA models.
Results: The 592 participants had a median age of 34 years; median baseline CD4þ
count was 629 cells/ml; the mean follow-up was 3.4 years. ART was used for 94 and
32% of accrued person-years in the immediate and deferred groups, respectively. There
was no difference between the immediate and deferred ART groups in QNPZ-8 change
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through follow-up [0.018 (95% CI 0.062 to 0.027, P¼0.44)], or at any visit.
However, QNPZ-8 scores increased in both arms during the first year, by 0.22 and
0.24, respectively (P<0.001 for increase from baseline).
Conclusion: Weobserved substantial improvement in neurocognitive test performance
during the first year in both study arms, underlining the importance of using a control
group in studies assessing neurocognitive performance over time. Immediate ART
neither benefitted nor harmed neurocognitive performance in individuals with
CD4þ cell counts above 500 cells/ml.
Copyright  2018 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
In advanced, untreated HIV infection, 15–20% of
individuals develop HIV-associated dementia (HAD)
[1,2], the severe form of HIV-associated neurocognitive
disorders (HAND) [3]. HAND is a subcortical dementia
that results in psychomotor slowing and is associated with
increased risk of mortality [4], job loss, [5] and poor
medication adherence [6]. Combination antiretroviral
therapy (ART) improves neuropsychological perfor-
mance in 40–60% of individuals with HAD [7–9].
ART regimens with higher versus lower central nervous
system (CNS) penetration may effect greater improve-
ment in individuals with HAD [10,11].
In acute HIV type 1 (HIV-1) infection, mild neurological
manifestations occur in up to 50% of individuals and
prompt clinical resolution is usually observed with
immediate ART [12]. In this setting, neuronal injury
may occur with raised levels of neurofilament light chain
in the cerebrospinal fluid (CSF) and altered ratios of CNS
metabolites in brain magnetic resonance imaging [13].
Therefore, plausibly, early ART may preserve neurologi-
cal function, or reverse neurological damage caused by
HIV infection. However, it is unclear if such benefit
occurs at high CD4þ cell counts and whether it might be
counteracted by potential ART toxicities [14].
We undertook the Neurology substudy of the Strategic
Timing of Antiretroviral Treatment (START) trial to test
the hypothesis that immediate versus deferred ART
would benefit neurocognitive performance in antiretro-
viral-naı¨ve adults with greater than 500 CD4þ cells/ml.
Methods
Study design
START is a large international, multicentre clinical trial,
performed by the International Network for Strategic
Initiatives in Global HIV Trials (INSIGHT). START
randomized 4684 ART-naı¨ve, HIVþ participants with
CD4þ cell counts greater than 500 cells/ml to receive
immediate versus deferred ART until the CD4þ cell
count fell to less than 350 cells/ml [15]. At selected sites,
the Neurology Substudy co-enrolled participants who
underwent a standard neuropsychological test battery at
baseline, months 4, 8, 12, and annually thereafter to
compare changes in neuropsychological test performance
in the immediate versus deferred groups (described
elsewhere) [16]. We report results on data accrued
through 26 May 2015, the day before the parent START
study was unblinded and all participants in the deferred
ART group were recommended to initiate ART because
immediate ART was found to have decreased the risk of
serious AIDS and non-AIDS illnesses by 57% [15].
Study population
The START Neurology substudy co-enrolled 608
participants between May 2009 and June 2012 at 35 sites
in Argentina, Australia, Belgium, Brazil, Chile, Germany,
Italy, Switzerland, Thailand, the United Kingdom, and
the USA. At participating sites, all eligible participants
were offered substudy co-enrollment. Eligibility criteria
included START co-enrollment and ability to perform the
study tests. The substudy was approved byeach institution’s
Institutional Review Board. Participant information and
consent forms were translated as required. All participants
provided written informed consent.
Neuropsychological test battery
The neuropsychological test battery consisted of eight
tests (grooved pegboard, finger tapping, Color Trails 1
and 2, Semantic Verbal Fluency, WAIS-III Digit Symbol,
HVLT-R Learning, HVLT-R Delayed Recall), covering
six cognitive domains (Supplemental Appendix, Table S1
footnote, http://links.lww.com/QAD/B233) that are
affected by HAND [3]. The test battery was constructed
to be adaptable across different cross-cultural, interna-
tional settings [17], to be brief, easy to administer and
score, and sensitive to HIV-associated brain injury [3].
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The Center for Epidemiological Studies-Depression
(CES-D) scale [18] was administered at each substudy
visit. A CES-D score 16 or greater was considered to
indicate depression.
Details of training, translations, administration of tests
and questionnaires, and staff accreditation are described
elsewhere [16].
Outcome measures
Test scores were standardized to z-scores using the baseline
test results of the 608 study participants as a reference
(internal standardization), resulting in mean¼ 0, SD¼ 1 at
baseline for each test (for detailed description and rationale
see [16]). Standardization of the Semantic Fluency test was
an exception: because we used alternate Semantic Fluency
test versions across visits to minimize practice effect,
we standardized its z-scores at each follow-up visit to
mean¼ 0 and SD¼ 1 using each visit’s pooled study
population as reference. The quantitative neuropsycho-
logical performance z-score (QNPZ-8) was calculated as
the average of the z-scores for the eight-test battery.
Primary outcome
The primary outcome was the change in the QNPZ-8
from baseline through follow-up.
Secondary outcomes
Secondary outcomes included individual test z-scores,
neurocognitive impairment (NCI), and a Global Deficit
Score (GDS). We defined NCI based on a cognitive
domain impairment score rating in line with the Frascati
criteria [3]; we did not assess for functional status or
confounding factors. Mild NCI [comparable with
asymptomatic NCI and early mild neurocognitive
disorder (MND) [3]] was defined as having internally
standardized z-scores 1 SD below zero in two or more
of the six cognitive domains; moderate/severe NCI
(comparable with advanced MND and HAD [3]) was
defined as having z-scores 2 SD below zero in two
or more domains. Due to internal standardization, the
sample mean of z-scores at baseline is zero.
The GDS was computed as the average of deficit scores for
the eight tests; the deficit scores grade normal performance
and impairment into 6 categories: 0 (normal), z greater or
equal1; 1 (mild),1 greater thanz greateror equal1.5;
2 (mild–moderate), 1.5 greater than z greater or equal
2; 3 (moderate),2 greater than z greater or equal2.5;
4 (moderate–severe),2.5 greater than z greater or equal
3; and 5 (severe), z less than 3. With the GDS, low
performance on some tests is not cancelled out by high
performance on others [19].
Antiretroviral therapy use
ART regimens were selected (‘prespecified’) prior to
randomization by site investigators from a table of
regimens recommended by the US Department of Health
and Human Services (see appendix in [15]). We calculated
CNS penetration effectiveness (CPE) scores of partici-
pants’ ART regimens using the 2010 version [20].
Other data collection
In addition to data collected in the parent study [15], the
Neurology substudy collected rural or urban residence,
current employment status, and education level. The
Framingham 10-year risk of coronary heart disease was
calculated as a cardiovascular health measure [21].
Statistical methods
The primary analysis for the Neurology substudy was an
intent-to-treat comparison between the immediate and
deferred ART groups for changes in QNPZ-8 from
baseline through follow-up, using a longitudinal mixed
model with an indicator variable for treatment group,
adjusted for visit and for baseline QNPZ-8 scores. The
sample size of 600 participants was estimated to detect an
average treatment difference in the change in QNPZ-8
scores between the two study arms of 0.13 with 80%
power at a 5% significance level.
A detailed description of statistical methods is included
in the Supplemental Appendix, http://links.lww.com/
QAD/B233. For all analyses, follow-up was censored at
each participant’s last visit prior to 27 May 2015, when
the parent START study was unblinded. To illustrate the
differential use of ART in the immediate and deferred
groups and its effect on CD4þ cell counts and HIV RNA
levels through follow-up, the proportion of participants
using ART, the proportion of participants with HIV
RNA levels of 200 copies/ml or less and the mean change
in CD4þ cell counts were summarized by treatment
group in 4-month intervals. The treatment difference in
change in CD4þ cell counts through follow-up was
estimated in a longitudinal mixed model adjusted for visit
and baseline CD4þ.
In addition to the primary analysis, we also compared
treatment groups for changes in QNPZ-8 from baseline
through month 12 only. By design, participants in the
immediate group were to initiate ART at randomization,
whereas few participants in the deferred group initiated
ART within the first year; therefore, the difference
between treatment groups over the first 12 months is an
approximate estimate of the effect of ART versus no ART
use. We performed similar intent-to-treat comparisons of
changes in z-scores for each of the eight tests as planned
per protocol. Within each treatment group, changes in
QNPZ-8 and individual z-scores from baseline to annual
visits were summarized by means with 95% confidence
intervals (CIs). Groups were compared for changes from
baseline to each visit using t-tests in linear regression
models adjusted for baseline scores. We compared
treatment groups for changes in the prevalence of NCI
and depression from baseline through follow-up using
generalized estimating equations (GEE) for binary
START neurology substudy Wright et al. 987
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responses, and used chi-squared tests to compare
prevalence at each visit. We compared treatment groups
for changes in GDS using longitudinal mixed models
adjusted for visit and baseline GDS. We compared
treatment groups for changes in CES-D scores using
similar longitudinal mixed models.
To assess the effect of ART versus strictly untreated HIV,
we also compared the immediate group (excluding
participants who did not start ART within the first year)
versus the deferred group (censored at ART start) for
changes in QNPZ-8 and individual z-scores; this
comparison is not protected by randomization.
Subgroup analyses for the primary endpoint were
performed to determine whether the treatment effect
differed across baseline characteristics. The homogeneity
of the treatment effect across subgroups was assessed by
testing for interaction between the subgroup variable and
treatment group indicator in longitudinal mixed models;
whenever possible, the continuous subgroup variable was
used to test for homogeneity. To adjust for multiple
comparisons, we used the Benjamini–Hochberg method
to limit the false discovery rate (FDR) to 5%.
Analyses were performed with SAS version 9.4 (SAS
Institute, Cary, North Carolina, United States) and R
version 3 [22]. All P values are two-sided; P 0.05
denotes significance.
Results
Baseline demographics, laboratory, and clinical
characteristics
Key baseline characteristics of substudy participants are
summarized in Table 1; 592 of the 608 participants had
neuropsychological test data at baseline and follow-up,
and were included in the current analyses (Fig. 1). Using
the cognitive domain impairment rating, we found that
19.8% of participants were at least mildly impaired, and
2.7% were moderately or severely impaired; the median
GDS was 1 (IQR 0–3) (Table 1). Baseline neuropsycho-
logical test results are summarized in Table S1 (Supple-
mental Appendix, http://links.lww.com/QAD/B233).
There was no difference between study arms in any of the
baseline factors.
Antiretroviral therapy use, HIV RNA, and CD4R
cell counts through follow-up
Participants were followed for a mean of 3.4 years (range
0.2–5.4 years). By design, ART use differed substantially
between treatment groups. In the immediate ART group,
291 (93.1%) of participants started ARTwithin 2 months
of randomization, and 92.8% or more used ART at any
follow-up visit (Fig. 2a). In the deferred ART group,
11.9, 34.8, 56.7, and 70.8% were using ART at months
12, 24, 36, and 48, respectively (Fig. 2a). ART was used
for 94.2% of follow-up time accrued in the immediate
group, and for 31.8% in the deferred group (Fig. 2b).
During the first year, ARTwas used for 91.5% of follow-
up time in the immediate group compared with 4.4% in
the deferred group.
Differences in ART use between the groups were
reflected in the HIV RNA and CD4þ levels. For almost
all participants, viral load was suppressed while using
ART (Fig. 2a). Through follow-up, mean CD4þ cell
counts were higher in the immediate ART group, by
226 cells/ml (95% CI 201–250, P< 0.001) (Fig. 2c).
Mean CD4þ cell counts at ART commencement were
676 and 411 cells/ml in the immediate and deferred ART
groups, respectively.
Neuropsychological test performance through
follow-up
The trajectories for mean change in QNPZ-8 in the
immediate and deferred ART groups were almost
identical; mean QNPZ-8 scores increased substantially
from baseline through month 12, by 0.22 and 0.24,
respectively (P< 0.001 each for increase), and remained
stable afterwards (Fig. 3a, and Supplemental Appendix,
Table S2A, http://links.lww.com/QAD/B233). There
was no difference between treatment groups in change in
QNPZ-8 from baseline through follow-up [estimated
difference 0.02 (95% CI 0.06 - 0.03, P¼ 0.44)], or
from baseline to any of the follow-up visits (Fig. 3, and
Supplemental Appendix, Table S2A, http://links.lww.
com/QAD/B233).
When considering individual tests, we found no
difference between treatment groups for seven of the
eight tests (P¼ 0.08–0.94 for comparing mean change in
z-scores through follow-up; Fig. 3b, and Supplemental
Appendix, Tables S2B-I, http://links.lww.com/QAD/
B233). For the Digit Symbol test, while performance
increased in both arms, the z-score increase was lower in
the immediate ART group, with an estimated treatment
difference through follow-up of0.12 (95% CI0.21 to
0.04, P¼ 0.005) favouring the deferred ART group
(Supplemental Appendix, Table S2D, http://links.lww.
com/QAD/B233).
The pattern of an initial marked increase in z-scores
through month 12 in both treatment groups was apparent
for the Grooved Pegboard, Color Trails 1 and 2, and
WAIS Digit Symbol tests. z-scores for the HVLT-R
Learning test also increased over time. For Semantic
Verbal Fluency, only the treatment difference, but not the
overall increase or decrease from baseline could be
estimated because z-scores for this test were standardized
to zero at each follow-up visit to account for the different
test versions used at different study visits.
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Sensitivity analyses showed similar results, when compar-
ing treatment groups through month 12 only (Supple-
mental Appendix, Tables S2A-I, http://links.lww.com/
QAD/B233), and when excluding participants who did
not start ARTwithin the first year in the immediate ART
group and censoring follow-up at ART initiation in the
deferred group (Supplemental Fig. S1, http://links.lww.
com/QAD/B234).
The prevalence of NCI (not corrected for practice effect
at follow-up) and changes in mean GDS are shown in the
Supplemental Appendix, Tables S3 and S4, http://
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Table 1. Baseline characteristics.
Median (IQR) or N (%)
Characteristic Immediate ART (n¼291) Deferred ART (n¼301) Total (n¼592)
Age (years) 33 [27–42] 35 [28–44] 34 [27–42]
Female (%) 27 (9.3%) 40 (13.3%) 67 (11.3%)
Race (%)
Black 38 (13.1%) 52 (17.3%) 90 (15.2%)
Latino/Hispanic 49 (16.8%) 47 (15.6%) 96 (16.2%)
Asian 45 (15.5%) 50 (16.6%) 95 (16.0%)
White 140 (48.1%) 140 (46.5%) 280 (47.3%)
Other 19 (6.5%) 12 (4.0%) 31 (5.2%)
Highest formal training (%)
No formal training 58 (19.9%) 63 (20.9%) 121 (20.4%)
Vocational training, completed 72 (24.7%) 73 (24.3%) 145 (24.5%)
Some college or university 73 (25.1%) 69 (22.9%) 142 (24.0%)
Bachelor’s degree or equivalent 65 (22.3%) 71 (23.6%) 136 (23.0%)
Master’s degree or higher 23 (7.9%) 25 (8.3%) 48 (8.1%)
Currently employed (%) 231 (79.4%) 221 (73.4%) 452 (76.4%)
Urban residence (%) 253 (86.9%) 266 (88.4%) 519 (87.7%)
Country of enrollment (%)
United Kingdom/Australia 33 (11.3%) 33 (11.0%) 66 (11.1%)
European countriesa 47 (16.2%) 55 (18.3%) 102 (17.2%)
United States 42 (14.4%) 45 (15.0%) 87 (14.7%)
Thailand 42 (14.4%) 47 (15.6%) 89 (15.0%)
Brazil 85 (29.2%) 80 (26.6%) 165 (27.9%)
Argentina/Chile 42 (14.4%) 41 (13.6%) 83 (14.0%)
Time since HIV diagnosis (years) 0.8 [0.2–2.5] 0.9 [0.3–2.5] 0.9 [0.3–2.5]
Likely mode of HIV infection (%)
Injection drug use 4 (1.4%) 1 (0.3%) 5 (0.8%)
Male sexual contact, same sex 222 (76.3%) 220 (73.1%) 442 (74.7%)
Sexual contact, opposite sex 53 (18.2%) 62 (20.6%) 115 (19.4%)
Other/unknown 12 (4.1%) 18 (6.0%) 30 (5.1%)
CD4þ cell count (cells/ml) 632 [578–745] 628 [570–735] 629 [575–741]
Nadir CD4þ cell count (cells/ml) 535 [466–626] 534 [473–638] 535 [471–631]
CD4þ:CD8þ ratio 0.64 [0.46–0.84] 0.63 [0.47–0.85] 0.64 [0.47–0.84]
HIV RNA (copies/ml) 18126 [5260–46700] 13317 [3609–41357] 15441 [4595–44700]
BMI (kg/m2) 23.8 [21.5–26.7] 23.7 [21.8–27.0] 23.8 [21.6–26.8]
Prior CVD diagnosisb (%) 5 (1.7%) 3 (1.0%) 8 (1.4%)
Framingham 10-year risk of CHD 1.7 [0.5–4.6] 2.0 [0.6–4.9] 1.8 [0.5–4.7]
Hepatitis B or C (%) 21 (7.3%) 16 (5.3%) 37 (6.3%)
Alcoholism/other substance dependence (%) 15 (5.2%) 16 (5.3%) 31 (5.2%)
Psychiatric diagnosisc (%) 28 (9.6%) 21 (7.0%) 49 (8.3%)
CES-D scored 10 [5–17] 10 [5–19] 10 [5–18]
CES-D scored  16 (%) 86 (31.6%) 92 (31.9%) 178 (31.8%)
GDSe 1 [0–2] 1 [0–3] 1 [0–3]
Mild impairmentf (%) 50 (17.2%) 67 (22.3%) 117 (19.8%)
Moderate impairmentf (%) 7 (2.4%) 9 (3.0%) 16 (2.7%)
CPE scoreg, prespecified ART regimen 7 [7–8] 7 [7–8] 7 [7–8]
ART, antiretroviral therapy; CES-D, Center for Epidemiological Studies-Depression; CVD, cardiovascular disease; GDS, Global Deficit Score IQR,
interquartile range.
aGermany, Italy, Belgium, and Switzerland.
bHistory of myocardial infarction, stroke, or coronary revascularization.
cMajor depression, bipolar disorder, schizophrenia, or other psychotic disorder.
dCenter for Epidemiological Studies Depression scale, 16 or greater denotes depression.
eGlobal Deficit Score, average of deficit scores over eight tests, where the deficit score for an individual test is defined by its z-scores, with 0 for z
1, 1 for 1 > z  1.5, 2 for 1.5 > z  2.0, 3 for -2.0 > z  2.5, 4 for 2.5 > z  3.0, 5 for z <3.0.
fz-scores below 1 (for mild impairment) or below 2 (for moderate impairment) for two or more of the six tested domains.
gCentral nervous system penetration effectiveness score.
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links.lww.com/QAD/B233, respectively; there was no
evidence for a difference between treatment groups.
Depressive symptoms
There was no difference between treatment groups
regarding change in continuous CES-D scores, estimated
difference 0.59 (95% CI 1.63 to 0.45, P¼ 0.27)
for longitudinal comparison (Supplemental Appendix,
Table S5, http://links.lww.com/QAD/B233). Depres-
sion prevalence (CES-D 16) was similar in both groups
(P¼ 0.21; Supplemental Appendix, Table S6, http://
links.lww.com/QAD/B233).
Subgroup analyses
Figure 4 illustrates treatment differences for the change in
QNPZ-8 across several subgroups; of these, subgroup
analyses by age, education, baseline HIV RNA, baseline
QNPZ-8, prespecified ART regimens, and CPE score
were defined a priori. We analysed 24 subgroup factors,
listed in the footnote to Fig. 4.
Among participants whose prespecified regimens
included efavirenz, the deferred ART group improved
their QNPZ-8 score slightly more than the immediate
group, estimated mean difference 0.05 (95% CI 0.10
990 AIDS 2018, Vol 32 No 8
Fig. 1. Study design and CONSORT flow diagram.
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to 0.00). In contrast, among participants with other
prespecified ART, the immediate arm showed greater
improvement in their QNPZ-8 scores than the deferred
arm, estimated difference 0.11 (95% CI 0.01–0.20;
P¼ 0.004 for heterogeneity of the treatment effect;
Fig. 4). Importantly, participants who were prespecified
ART without efavirenz differed from those who were
prespecified efavirenz in several characteristics that may
impact upon neurocognitive test performance, including
a higher prevalence of prior psychiatric diagnoses (20.6
versus 4.9%) and depression (CES-D score 16, 43.3
versus 28.6%; Supplemental Appendix, Table S7, http://
links.lww.com/QAD/B233).
Additionally, the treatment difference between the
immediate and deferred groups varied across subgroups
by baseline QNPZ-8 scores (P< 0.001 for heterogeneity)
and by the baseline global deficit score (P¼ 0.004). There
was no evidence for a difference in mean QNPZ-8
change between the immediate and deferred ART groups
within any of the investigated subgroups, however, except
for the subgroup of participants who were not
prespecified EFV (Fig. 4).
Discussion
The START Neurology substudy is the largest controlled
clinical trial to evaluate the impact of ART on
neurocognitive performance among HIV-positive indi-
viduals with CD4þ cell counts greater than 500 cells/ml.
We found no difference in the change in neuropsycho-
logical test performance when comparing immediate
versus delayed ART in previously untreated, HIV-
positive adults with CD4þ cell counts above 500 cells/
ml. Thus, the study’s hypothesis that immediate versus
delayed ART would have a favourable effect on
neurocognitive performance was refuted. As a corollary,
we found that early ART neither benefits nor harms
neurocognitive performance.
Why was there no beneficial effect of immediate ARTon
neurocognitive performance, given that benefit has been
reported in previous studies [7–9]? This study was well
powered to detect a modest treatment difference. There
was no difference between the outcomes in the two arms
evaluated either by intent-to-treat or in sensitivity
analyses. During the first year, ART was used for
91.5% of the follow-up time accrued in the immediate
group, compared with 4.4% in the deferred group, and
undetectable HIV-RNA levels were observed on ART;
therefore, the study’s finding could not be explained by
ineffective ART, or poor adherence.
It is highly likely that practice effect influenced the sharp,
near-identical increase in aggregate test performance
(QNPZ-8) in both study arms through month 12.
Practice effect occurs following the repeated adminis-
tration of neuropsychological tests and is well docu-
mented [23,24], but often ignored in Neuro-HIV studies
[25]. The trajectories we observed are similar to those
seen with repeated testing in healthy persons, or in HIV-
positive persons who are clinically stable on ART [26].
Of note, participants in both study arms achieved the
same incremental improvement in QNPZ-8 from
baseline to year 1, and the improvement was orders of
magnitude larger than any differences between the
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Fig. 2. (a) Percentage of participants using ART, and percentage with suppressed viral load (HIV RNA<— 200copies/ml) over
time; (b) ART use expressed as percentage of follow-up time accrued; and (c) mean CD4R cell count levels (W2 SE) over time.
ART, antiretroviral therapy.
 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
immediate and deferred ART groups. In previous
Neuro-HIV studies that reported beneficial effects of
ART, all participants started ARTat studyentry, there was
no control group of delayed ART, no adjustment for
practice effect, and the observed improvement in test
performance was attributed to ART [7–9]. Our findings
contradict conclusions drawn from uncontrolled pro-
spective studies and underline the importance of a
control arm in studies assessing neurocognitive test
performance over time.
The likeliest biological explanation for the observed lack
of effect of immediate ART is that there was little HIV-
induced neural injury in our study population, despite the
presumed presence of HIV in CSF and local inflamma-
tion within at least some of the participants. Study
participants were young, urban, educated, mostly
employed, and without rapid immune progression; these
factors may have afforded neuropsychological protection
against the effect of HIV, and as a result neuropsycholog-
ical performance was not remediated by immediate ART.
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Fig. 3. (a) Change in mean QNPZ-8 scores from baseline through follow-up; (b) change in mean z-scores for the individual tests,
which are averaged to calculate the QNPZ-8 summary score.
 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
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Fig. 4. Subgroup analyses for change in mean QNPZ-8 scores from baseline. After adjusting interaction P values for multiple
comparisons using the Benjamini–Hochberg false discovery rate (FDR) method, P0.004 provides evidence for heterogeneity of
the treatment effect across subgroups at the FDR 0.05 level. Subgroup analyses by age, education, HIV RNA level, prespecified
ART regimens, and their CNS penetration effectiveness score were specified a priori in the study protocol. In addition to the eight
subgroup factors shown, we analyzed subgroups by 16 baseline factors: by race, sex, employment status, urban residence, country
of enrollment, time since HIV diagnosis, CD4þ cell count, BMI, diabetes, depression (CES-D 16), prior psychiatric diagnosis,
prior cardiovascular disease, 10-year Framingham risk of CHD, hematocrit, AST/SGOT, ALT/SGPT. The treatment effect was
homogeneous across those 16 subgroups. ART, antiretroviral therapy; CNS, central nervous system.
 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
With respect to the possibility that ART may have
contributed to CNS toxicity, and hence abrogated any
possible benefit of immediate ART, use of ARTregimens
with high CNS penetration effectiveness scores neither
benefitted, nor disadvantaged either treatment group.
Similarly, with respect to the potential toxicity from
efavirenz, those participants whose prespecified ART
regimen did not include efavirenz had slightly greater
neuropsychological improvement in the immediate
versus the deferred group. However, comparing efavirenz
to other ART is based on a nonrandomized analysis that
needs to be interpreted cautiously, as those participants
who were prespecified efavirenz differed markedly from
those prespecified other ART.
It is possible that immediate ART in individuals with
high CD4þ cell counts protects neural health in ways
that were not captured by the neurocognitive tests used
in this study, or that will only manifest in a delayed
fashion. For example, early treatment might reduce or
stop expansion of the CNS HIV reservoir, potentially
resulting in longer-term benefit [27]. Other measures of
ongoing neural injury, including CSF or blood
biomarkers such as neurofilament light chain (NFL)
[28–30] or neuroimaging modalities [31], may eventu-
ally prove to be more sensitive and robust than the
neurocognitive test performance. On the other hand, in
the absence of confounding conditions, neurocognitive
performance has been the evaluation and diagnostic
standard for assessing the impact of HIV on CNS
functional integrity [32,33], and was not appreciably
altered by early compared with delayed therapy in
this study.
The study’s chief strengths were its randomized design,
the large sample size, and the standardized test battery
administration. There were several limitations. First,
mean follow-up was 3.4 years and, plausibly, an ART
effect could emerge after longer treatment duration.
Notwithstanding, there was no evidence for a divergence
of treatment arms in the study’s later years. Second, the
test battery was limited to eight neuropsychological tests.
However, the battery constitutes tests shown to be highly
correlated with cognitive performance on a larger battery
[34]. Lastly, we have not measured biomarkers of
neural injury or the size of the HIV reservoir in
cerebrospinal fluid.
In conclusion, we observed a striking improvement of test
performance during the first year in both study arms,
which underlines the need for a control group in studies
assessing neurocognitive test performance over time. The
parent START study showed that immediate ART
significantly decreases risk of serious AIDS and non-
AIDS conditions, leading to the 2015 WHO recom-
mendation that all HIV-positive individuals should
initiate ART irrespective of CD4þ cell counts [35].
However, the START Neurology substudy shows neither
benefit, nor harm of early ART with respect to
neurocognitive performance in individuals with CD4þ
cell counts above 500 cells/ml.
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Research in Context
Evidence before this study: In advanced, untreated
Human Immunodeficiency Virus type 1 (HIV-1)
infection, 15–20% of individuals develop HIV-associated
dementia (HAD). Combination antiretroviral therapy
(ART) improves neuropsychological performance in 40–
60% of individuals with HAD. In acute HIV-1 infection,
mild neurological manifestations occur in up to 50% of
individuals and clinical resolution is usually observed with
immediate ART. However, it is unclear if such benefit
occurs in HIV-positive individuals with high CD4þ cell
counts and whether any benefit might be counteracted by
potential ART toxicities, which have been reported in
individuals receiving ART regimens that have high
penetration into the brain.
Added value of this study: We undertook a Neurology
substudy within the Strategic Timing of Antiretroviral
Treatment (START) study. The START Neurology
substudy which enrolled 608 participants is the largest
clinical trial to date to evaluate the impact of ART
on neurocognitive performance in HIV-positive, ART-
naive individuals with greater than 500 cells/ml.
Our study found that participants randomized to
commence ART immediately versus deferring ART
until CD4þ less than 350 cells/ml did not experience
either benefit or harm with respect to their neurocog-
nitive performance, during a mean follow-up period of
3.4 years. ARTregimens with high brain penetration did
not benefit or advantage either treatment group.
Importantly, we observed a marked improvement in
neurocognitive test performance in both study arms
during the first 12 months, strongly suggesting a practice
effect.
Implications of all the available evidence: Our finding
suggests that there was minimal underlying neurological
damage that could be either prevented or reversed by
immediate ART in this study population. The START
parent study showed that immediate versus deferred ART
decreases the risk of serious AIDS and non-AIDS illnesses
by 57%. These pivotal findings led to the 2015 World
Health Organization recommendation that all HIV-
positive individuals should initiate ART irrespective of
CD4þ cell counts, and the START Neurology substudy
findings support the safety of initiating ARTwith respect
to neurocognitive performance. Our study also under-
lines the importance of having a control arm in
intervention studies that evaluate neurocognitive test
performance over time.
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